Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...

Virus-associated cancers are a significant and persistent global health challenge, providing unique insight into the relationship between chronic infection ...

Immune system activation and activity is regulated through stimulatory or inhibitory ligand-receptor interactions collectively termed immune checkpoints. 1 Stimulatory interactions give the immune ...

Adding the immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab to percutaneous hepatic perfusion may improve survival outcomes in patients with ...

Study results suggest immune checkpoint inhibitor therapy may offer immunomodulatory benefits for patients with asthma and ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not ...

LAG-3 and TIGIT expression may predict skin melanoma progression and survival. Discover how these immune markers could shape future therapies. Read more.

Skin cancers, lung cancers, lymphomas—though these cancers affect different parts of the body, they can all be treated with one of the latest therapies medicine has to offer: checkpoint inhibitors.

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar ...

Please provide your email address to receive an email when new articles are posted on . More than 7% of patients receiving immune checkpoint blockade therapy and antibiotics developed immune-related ...